Open this publication in new window or tab >>Show others...
2024 (English)In: Cancers, ISSN 2072-6694, Vol. 16, no 23, article id 3942Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Current challenges in meningioma treatment, including post-surgical complications and cognitive impairments, highlight the need for new treatment alternatives. Immunological interventions have shown promise. However, there is a knowledge gap in characterizing infiltrating immune cells in meningioma and their interplay. Further studies on immune cells in single-cell suspensions from digested meningioma tissues could identify targetable mechanisms for non-surgical treatment options with fewer side effects. This study aimed to optimize a protocol for faster digestion of meningioma tissues into viable single-cell suspensions and to identify infiltrating immune cell populations.
METHODS: We modified a commercial kit intended for whole skin dissociation to digest resected meningioma tissues into viable single-cell suspensions. Tumor-infiltrating immune cell populations were characterized using flow cytometry.
RESULTS: , with a small proportion co-expressing CD83. Women were more likely to have a lower proportion of immune cells, B cells, and NK cells. Female patients with a high proportion of immune cells had a higher proportion of macrophages.
CONCLUSION: We successfully optimized a protocol for generating single-cell suspensions with viable immune cells from meningioma tissues, revealing infiltrating antigen-presenting cells with an immunosuppressive phenotype, and lymphocytes. This short protocol allows advanced analyses of tumor-infiltrating cells using techniques such as single-cell RNA sequencing and flow cytometry, which require live, dissociated cells.
Place, publisher, year, edition, pages
MDPI, 2024
Keywords
T cells, TIM-3, brain tumor, immune cells, lymphocytes, macrophages, meningioma, single-cell suspension, tumor digestion, tumor-infiltrating cells
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:mau:diva-72847 (URN)10.3390/cancers16233942 (DOI)001376117400001 ()39682129 (PubMedID)2-s2.0-85211949815 (Scopus ID)
2024-12-202024-12-202025-01-28Bibliographically approved